Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
This is understandable but counterproductive
That gap, about 3 to 4 percentage points, is statistically meaningful but requires context to interpret properly
For people currently managing obesity and who are not yet on treatment or who are on GLP-1 therapy but not achieving their desired outcomes the most appropriate step is a conversation with a qualified healthcare professional
Advise patients that there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ZEPBOUND during pregnancy [see Use in Specific Populations (8.1)]
With A1C reductions up to 2.24%, tirzepatide offers the most potent glucose-lowering effect of any incretin-based therapy currently available
US$ 25.52
US$ 27.58
US$ 21.62
US$ 28.07
US$ 29.39
US$ 25.28
US$ 26.60
US$ 20.86
US$ 24.68
US$ 22.89
US$ 24.00
US$ 25.98
US$ 25.05
US$ 23.47
